| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenoviruses, Human | 52 | 2023 | 257 | 13.560 |
Why?
|
| Corneal Diseases | 63 | 2023 | 636 | 11.640 |
Why?
|
| Cornea | 79 | 2023 | 1524 | 10.000 |
Why?
|
| Keratitis | 23 | 2023 | 268 | 8.740 |
Why?
|
| Prostheses and Implants | 49 | 2023 | 1387 | 6.340 |
Why?
|
| Stevens-Johnson Syndrome | 30 | 2022 | 281 | 6.110 |
Why?
|
| Adenovirus Infections, Human | 22 | 2020 | 71 | 6.080 |
Why?
|
| Eye Infections, Bacterial | 14 | 2022 | 235 | 4.830 |
Why?
|
| Keratoconjunctivitis | 14 | 2021 | 53 | 4.730 |
Why?
|
| Artificial Organs | 23 | 2023 | 204 | 4.610 |
Why?
|
| Adenoviridae Infections | 14 | 2022 | 96 | 4.180 |
Why?
|
| Prosthesis Implantation | 25 | 2023 | 642 | 4.070 |
Why?
|
| Burns, Chemical | 13 | 2023 | 159 | 3.750 |
Why?
|
| Corneal Ulcer | 13 | 2023 | 169 | 3.750 |
Why?
|
| Eye Burns | 12 | 2020 | 103 | 3.740 |
Why?
|
| Epithelium, Corneal | 13 | 2021 | 247 | 3.430 |
Why?
|
| Eye Infections, Viral | 8 | 2020 | 57 | 3.380 |
Why?
|
| Ophthalmology | 14 | 2023 | 508 | 3.380 |
Why?
|
| Corneal Transplantation | 14 | 2021 | 386 | 3.280 |
Why?
|
| Eye Diseases | 17 | 2023 | 669 | 3.250 |
Why?
|
| Keratitis, Herpetic | 7 | 2021 | 81 | 2.700 |
Why?
|
| Eye Infections, Fungal | 8 | 2023 | 110 | 2.510 |
Why?
|
| Limbus Corneae | 7 | 2021 | 144 | 2.490 |
Why?
|
| Genome, Viral | 25 | 2022 | 667 | 2.380 |
Why?
|
| Polymethyl Methacrylate | 10 | 2021 | 145 | 2.290 |
Why?
|
| Conjunctiva | 12 | 2019 | 494 | 2.180 |
Why?
|
| Glaucoma | 17 | 2023 | 1159 | 2.020 |
Why?
|
| Endophthalmitis | 7 | 2023 | 262 | 1.980 |
Why?
|
| Capsid Proteins | 9 | 2016 | 479 | 1.940 |
Why?
|
| Conjunctival Neoplasms | 8 | 2017 | 79 | 1.880 |
Why?
|
| Sterilization | 4 | 2021 | 133 | 1.810 |
Why?
|
| Visual Acuity | 37 | 2022 | 2530 | 1.770 |
Why?
|
| Recombination, Genetic | 12 | 2022 | 1586 | 1.740 |
Why?
|
| Adenoviridae | 9 | 2022 | 1101 | 1.720 |
Why?
|
| Blindness | 7 | 2023 | 615 | 1.640 |
Why?
|
| DNA, Viral | 22 | 2019 | 2227 | 1.530 |
Why?
|
| Keratoplasty, Penetrating | 9 | 2022 | 155 | 1.490 |
Why?
|
| Gelatin | 2 | 2021 | 225 | 1.430 |
Why?
|
| Vitreous Body | 4 | 2015 | 389 | 1.290 |
Why?
|
| Titanium | 6 | 2020 | 494 | 1.280 |
Why?
|
| Evolution, Molecular | 13 | 2020 | 1939 | 1.170 |
Why?
|
| Conjunctival Diseases | 6 | 2019 | 122 | 1.170 |
Why?
|
| Anti-Bacterial Agents | 15 | 2022 | 7182 | 1.150 |
Why?
|
| Phylogeny | 26 | 2021 | 2804 | 1.130 |
Why?
|
| Conjunctivitis | 5 | 2022 | 158 | 1.100 |
Why?
|
| Eye Neoplasms | 4 | 2017 | 312 | 1.090 |
Why?
|
| Amnion | 7 | 2020 | 209 | 1.080 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 5 | 2017 | 123 | 1.060 |
Why?
|
| Corneal Stroma | 7 | 2017 | 174 | 1.030 |
Why?
|
| Alkalies | 3 | 2017 | 52 | 1.020 |
Why?
|
| Methacrylates | 2 | 2021 | 107 | 1.000 |
Why?
|
| Cross-Linking Reagents | 4 | 2021 | 694 | 0.960 |
Why?
|
| Humans | 256 | 2023 | 744366 | 0.950 |
Why?
|
| Corneal Neovascularization | 4 | 2020 | 188 | 0.930 |
Why?
|
| Interleukin-8 | 5 | 2021 | 690 | 0.930 |
Why?
|
| Adenovirus E3 Proteins | 2 | 2013 | 7 | 0.880 |
Why?
|
| Ophthalmologic Surgical Procedures | 10 | 2021 | 349 | 0.880 |
Why?
|
| Eye Infections | 4 | 2023 | 64 | 0.850 |
Why?
|
| Adenoviruses, Simian | 5 | 2023 | 14 | 0.840 |
Why?
|
| Corneal Edema | 2 | 2020 | 52 | 0.830 |
Why?
|
| Prosthesis Design | 9 | 2020 | 2110 | 0.800 |
Why?
|
| Eye Proteins | 5 | 2019 | 645 | 0.790 |
Why?
|
| Tissue Engineering | 2 | 2021 | 1880 | 0.790 |
Why?
|
| Stem Cell Transplantation | 4 | 2019 | 1620 | 0.780 |
Why?
|
| Eyelid Diseases | 6 | 2019 | 155 | 0.770 |
Why?
|
| Chemokine CCL2 | 6 | 2010 | 619 | 0.770 |
Why?
|
| Adenovirus E1A Proteins | 2 | 2019 | 76 | 0.750 |
Why?
|
| Viral Tropism | 4 | 2019 | 101 | 0.730 |
Why?
|
| Neglected Diseases | 2 | 2021 | 64 | 0.730 |
Why?
|
| beta-Alanine | 1 | 2020 | 74 | 0.720 |
Why?
|
| Herpes Zoster Ophthalmicus | 2 | 2021 | 36 | 0.720 |
Why?
|
| Hemangioma, Capillary | 1 | 2020 | 61 | 0.720 |
Why?
|
| School Admission Criteria | 1 | 2020 | 106 | 0.700 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 112 | 0.700 |
Why?
|
| Povidone-Iodine | 1 | 2019 | 59 | 0.680 |
Why?
|
| Lymphoid Tissue | 4 | 2007 | 455 | 0.680 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 264 | 0.680 |
Why?
|
| Glucocorticoids | 9 | 2021 | 2108 | 0.670 |
Why?
|
| Biology | 1 | 2021 | 295 | 0.660 |
Why?
|
| Intraocular Pressure | 13 | 2023 | 1270 | 0.660 |
Why?
|
| Gamma Rays | 4 | 2021 | 320 | 0.660 |
Why?
|
| Benzoates | 1 | 2020 | 217 | 0.660 |
Why?
|
| Personnel Selection | 1 | 2020 | 190 | 0.660 |
Why?
|
| Bioartificial Organs | 2 | 2015 | 49 | 0.650 |
Why?
|
| Rec A Recombinases | 1 | 2018 | 51 | 0.650 |
Why?
|
| Collagen | 4 | 2022 | 2688 | 0.630 |
Why?
|
| Microscopy, Confocal | 10 | 2020 | 1970 | 0.610 |
Why?
|
| Corneal Perforation | 2 | 2019 | 32 | 0.610 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2021 | 706 | 0.590 |
Why?
|
| Intensive Care, Neonatal | 1 | 2019 | 198 | 0.590 |
Why?
|
| Viral Proteins | 6 | 2022 | 1900 | 0.590 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2017 | 245 | 0.580 |
Why?
|
| Zinc Fingers | 1 | 2019 | 583 | 0.570 |
Why?
|
| Antifungal Agents | 5 | 2023 | 729 | 0.570 |
Why?
|
| Health Facilities | 2 | 2021 | 572 | 0.570 |
Why?
|
| Virus Internalization | 5 | 2020 | 502 | 0.560 |
Why?
|
| Alternaria | 2 | 2013 | 44 | 0.560 |
Why?
|
| Chemokine CXCL1 | 3 | 2016 | 101 | 0.550 |
Why?
|
| Sequence Analysis, DNA | 16 | 2019 | 4805 | 0.550 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2008 | 96 | 0.550 |
Why?
|
| Postoperative Complications | 14 | 2023 | 15297 | 0.550 |
Why?
|
| Sjogren's Syndrome | 5 | 2017 | 234 | 0.540 |
Why?
|
| 5' Untranslated Regions | 1 | 2017 | 249 | 0.540 |
Why?
|
| Electrons | 3 | 2021 | 268 | 0.540 |
Why?
|
| Keratoconus | 2 | 2017 | 121 | 0.530 |
Why?
|
| Rosacea | 3 | 2004 | 49 | 0.530 |
Why?
|
| Eye Injuries | 4 | 2023 | 245 | 0.530 |
Why?
|
| Eyelid Neoplasms | 1 | 2017 | 94 | 0.530 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2021 | 110 | 0.530 |
Why?
|
| Corneal Dystrophies, Hereditary | 3 | 2019 | 81 | 0.530 |
Why?
|
| Perforin | 1 | 2016 | 168 | 0.520 |
Why?
|
| Burn Units | 1 | 2016 | 136 | 0.520 |
Why?
|
| Light | 1 | 2021 | 1374 | 0.520 |
Why?
|
| Fas Ligand Protein | 1 | 2016 | 216 | 0.520 |
Why?
|
| Retrospective Studies | 48 | 2023 | 77460 | 0.520 |
Why?
|
| Contact Lenses | 4 | 2021 | 145 | 0.510 |
Why?
|
| Hemangioma | 1 | 2020 | 738 | 0.510 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2012 | 69 | 0.500 |
Why?
|
| Microsurgery | 1 | 2020 | 796 | 0.500 |
Why?
|
| Bacteria | 4 | 2023 | 2115 | 0.500 |
Why?
|
| Search Engine | 4 | 2022 | 144 | 0.490 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2019 | 1035 | 0.490 |
Why?
|
| Granzymes | 1 | 2016 | 271 | 0.490 |
Why?
|
| Schools, Medical | 1 | 2021 | 881 | 0.490 |
Why?
|
| Fluorescein Angiography | 1 | 2019 | 940 | 0.490 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2015 | 90 | 0.480 |
Why?
|
| Cicatrix | 1 | 2020 | 764 | 0.480 |
Why?
|
| Stem Cells | 3 | 2021 | 3567 | 0.470 |
Why?
|
| RNA, Viral | 5 | 2017 | 2901 | 0.470 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 3 | 2022 | 109 | 0.470 |
Why?
|
| Biological Evolution | 1 | 2019 | 1077 | 0.460 |
Why?
|
| Educational Measurement | 1 | 2020 | 1210 | 0.460 |
Why?
|
| Computational Biology | 16 | 2019 | 3519 | 0.460 |
Why?
|
| Health Personnel | 2 | 2021 | 3219 | 0.460 |
Why?
|
| Keloid | 1 | 2013 | 50 | 0.450 |
Why?
|
| Retina | 9 | 2020 | 2616 | 0.450 |
Why?
|
| Sweet Syndrome | 1 | 2013 | 47 | 0.450 |
Why?
|
| Carbonic Anhydrase Inhibitors | 2 | 2018 | 95 | 0.440 |
Why?
|
| Artificial Intelligence | 3 | 2020 | 2213 | 0.430 |
Why?
|
| Mouth Diseases | 1 | 2015 | 241 | 0.430 |
Why?
|
| Fibroblasts | 9 | 2021 | 4162 | 0.430 |
Why?
|
| Anterior Eye Segment | 3 | 2020 | 152 | 0.430 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2019 | 3873 | 0.420 |
Why?
|
| Tomography, Optical Coherence | 8 | 2023 | 2657 | 0.420 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2019 | 781 | 0.420 |
Why?
|
| Cryotherapy | 2 | 2011 | 155 | 0.420 |
Why?
|
| Disease Models, Animal | 13 | 2023 | 18034 | 0.420 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2016 | 571 | 0.420 |
Why?
|
| Acetazolamide | 1 | 2012 | 100 | 0.410 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 1480 | 0.400 |
Why?
|
| Critical Pathways | 1 | 2015 | 476 | 0.400 |
Why?
|
| Animals | 57 | 2023 | 168768 | 0.390 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2020 | 639 | 0.390 |
Why?
|
| Acanthamoeba Keratitis | 2 | 2021 | 17 | 0.390 |
Why?
|
| Rabbits | 11 | 2023 | 4894 | 0.390 |
Why?
|
| Surface Properties | 5 | 2021 | 1184 | 0.390 |
Why?
|
| Lacerations | 1 | 2013 | 144 | 0.390 |
Why?
|
| Microglia | 4 | 2021 | 1267 | 0.390 |
Why?
|
| Biological Dressings | 1 | 2011 | 30 | 0.390 |
Why?
|
| Bacterial Infections | 1 | 2019 | 1401 | 0.390 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 2047 | 0.370 |
Why?
|
| Monocytes | 5 | 2023 | 2596 | 0.370 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2011 | 484 | 0.370 |
Why?
|
| Administration, Topical | 5 | 2013 | 690 | 0.360 |
Why?
|
| Antiviral Agents | 3 | 2020 | 2987 | 0.360 |
Why?
|
| Ultraviolet Rays | 5 | 2022 | 1060 | 0.360 |
Why?
|
| Respiratory Tract Infections | 4 | 2016 | 961 | 0.360 |
Why?
|
| Algorithms | 4 | 2020 | 13882 | 0.350 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2009 | 60 | 0.350 |
Why?
|
| Middle Aged | 57 | 2023 | 213390 | 0.350 |
Why?
|
| Immunity, Innate | 3 | 2019 | 2962 | 0.350 |
Why?
|
| Neuroglia | 3 | 2020 | 928 | 0.350 |
Why?
|
| Hydrogels | 3 | 2021 | 724 | 0.340 |
Why?
|
| Disease Outbreaks | 6 | 2023 | 1771 | 0.340 |
Why?
|
| Gene Expression Regulation, Viral | 4 | 2019 | 442 | 0.340 |
Why?
|
| Dendritic Cells | 3 | 2016 | 2725 | 0.340 |
Why?
|
| Visually Impaired Persons | 1 | 2010 | 81 | 0.340 |
Why?
|
| Tissue Scaffolds | 3 | 2021 | 956 | 0.340 |
Why?
|
| Pandemics | 5 | 2022 | 8385 | 0.340 |
Why?
|
| Female | 79 | 2021 | 380193 | 0.340 |
Why?
|
| Sequence Alignment | 7 | 2019 | 2256 | 0.330 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2012 | 697 | 0.330 |
Why?
|
| Male | 76 | 2023 | 350115 | 0.330 |
Why?
|
| Epitopes | 1 | 2015 | 2571 | 0.330 |
Why?
|
| Societies, Medical | 1 | 2020 | 3743 | 0.330 |
Why?
|
| Bowman Membrane | 1 | 2008 | 2 | 0.320 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 1821 | 0.320 |
Why?
|
| Eyelids | 4 | 2020 | 265 | 0.320 |
Why?
|
| Tears | 4 | 2017 | 256 | 0.320 |
Why?
|
| RNA, Messenger | 6 | 2017 | 13035 | 0.320 |
Why?
|
| Aged | 46 | 2021 | 163288 | 0.320 |
Why?
|
| Clinical Competence | 2 | 2020 | 4687 | 0.320 |
Why?
|
| Fungi | 1 | 2011 | 327 | 0.310 |
Why?
|
| Respiratory Tract Diseases | 1 | 2013 | 722 | 0.310 |
Why?
|
| Virus Replication | 8 | 2019 | 2535 | 0.310 |
Why?
|
| Electronic Health Records | 4 | 2019 | 4468 | 0.310 |
Why?
|
| Adult | 54 | 2021 | 214052 | 0.310 |
Why?
|
| Sarcoma, Kaposi | 1 | 2011 | 370 | 0.310 |
Why?
|
| Acute Disease | 10 | 2019 | 7147 | 0.310 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 941 | 0.300 |
Why?
|
| Autoimmune Diseases | 4 | 2021 | 2134 | 0.300 |
Why?
|
| Capsid | 1 | 2010 | 437 | 0.300 |
Why?
|
| Macrophages | 4 | 2023 | 5660 | 0.300 |
Why?
|
| Laser Therapy | 2 | 2013 | 1072 | 0.300 |
Why?
|
| Tetracyclines | 2 | 2004 | 60 | 0.300 |
Why?
|
| Riboflavin | 3 | 2017 | 108 | 0.290 |
Why?
|
| Dry Eye Syndromes | 3 | 2023 | 386 | 0.290 |
Why?
|
| Liver Diseases | 1 | 2015 | 1253 | 0.280 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 1170 | 0.280 |
Why?
|
| NF-kappa B | 4 | 2009 | 2499 | 0.280 |
Why?
|
| Cells, Cultured | 12 | 2021 | 19233 | 0.280 |
Why?
|
| Cataract Extraction | 1 | 2011 | 481 | 0.280 |
Why?
|
| Interferon-alpha | 2 | 2008 | 895 | 0.280 |
Why?
|
| Protein Subunits | 1 | 2009 | 959 | 0.270 |
Why?
|
| Follow-Up Studies | 19 | 2023 | 39052 | 0.270 |
Why?
|
| Vitronectin | 1 | 2005 | 44 | 0.270 |
Why?
|
| Gelatinases | 2 | 2018 | 94 | 0.270 |
Why?
|
| Escherichia coli | 1 | 2018 | 4217 | 0.270 |
Why?
|
| Tropism | 1 | 2005 | 41 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 12 | 2020 | 21833 | 0.260 |
Why?
|
| Fever | 1 | 2013 | 1616 | 0.260 |
Why?
|
| Eye | 4 | 2022 | 729 | 0.260 |
Why?
|
| Oligopeptides | 2 | 2012 | 1189 | 0.260 |
Why?
|
| Acyclovir | 2 | 2020 | 272 | 0.260 |
Why?
|
| Hospitals, Special | 1 | 2006 | 101 | 0.260 |
Why?
|
| Scleritis | 2 | 2017 | 100 | 0.260 |
Why?
|
| Peroxidase | 3 | 2016 | 611 | 0.260 |
Why?
|
| Glaucoma Drainage Implants | 2 | 2019 | 116 | 0.260 |
Why?
|
| Matrix Metalloproteinases | 2 | 2019 | 391 | 0.260 |
Why?
|
| Temperature | 2 | 2021 | 2204 | 0.250 |
Why?
|
| Disease Management | 1 | 2015 | 2460 | 0.250 |
Why?
|
| Neutrophils | 2 | 2009 | 3721 | 0.250 |
Why?
|
| Lung Diseases | 1 | 2015 | 1887 | 0.250 |
Why?
|
| Base Sequence | 12 | 2018 | 12797 | 0.250 |
Why?
|
| Internet | 5 | 2022 | 3056 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 4034 | 0.240 |
Why?
|
| Fasciitis | 1 | 2005 | 65 | 0.240 |
Why?
|
| Retinal Diseases | 3 | 2018 | 684 | 0.240 |
Why?
|
| Blood Proteins | 3 | 2018 | 1124 | 0.240 |
Why?
|
| Cross Infection | 2 | 2020 | 1417 | 0.240 |
Why?
|
| Iris Diseases | 1 | 2004 | 40 | 0.230 |
Why?
|
| Kidney Diseases | 1 | 2015 | 2148 | 0.230 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 1917 | 0.230 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 452 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2010 | 4751 | 0.230 |
Why?
|
| Treatment Outcome | 15 | 2020 | 63107 | 0.230 |
Why?
|
| Internship and Residency | 2 | 2020 | 5791 | 0.230 |
Why?
|
| Aged, 80 and over | 19 | 2020 | 57776 | 0.230 |
Why?
|
| Molecular Sequence Data | 15 | 2013 | 18111 | 0.230 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2003 | 2455 | 0.230 |
Why?
|
| Vaccines | 2 | 2023 | 823 | 0.230 |
Why?
|
| Skin | 2 | 2016 | 4372 | 0.230 |
Why?
|
| Sporothrix | 1 | 2002 | 2 | 0.230 |
Why?
|
| Sporotrichosis | 1 | 2002 | 2 | 0.230 |
Why?
|
| Administration, Oral | 5 | 2020 | 3914 | 0.220 |
Why?
|
| Ferric Compounds | 1 | 2005 | 374 | 0.220 |
Why?
|
| Melanosis | 1 | 2004 | 78 | 0.220 |
Why?
|
| Organic Chemicals | 2 | 2021 | 211 | 0.220 |
Why?
|
| Smallpox | 1 | 2023 | 45 | 0.220 |
Why?
|
| Transplantation, Autologous | 3 | 2019 | 2124 | 0.220 |
Why?
|
| Dynamin II | 2 | 2020 | 35 | 0.220 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2021 | 164 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2023 | 4424 | 0.220 |
Why?
|
| Antiprotozoal Agents | 2 | 2020 | 86 | 0.210 |
Why?
|
| Vaccinia | 1 | 2023 | 76 | 0.210 |
Why?
|
| Intensive Care Units | 1 | 2016 | 3680 | 0.210 |
Why?
|
| Graft Rejection | 1 | 2015 | 4397 | 0.210 |
Why?
|
| Caprolactam | 1 | 2021 | 1 | 0.210 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2016 | 212 | 0.210 |
Why?
|
| Information Dissemination | 1 | 2010 | 1099 | 0.210 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2021 | 72 | 0.210 |
Why?
|
| Virulence | 3 | 2022 | 1333 | 0.210 |
Why?
|
| Biocompatible Materials | 5 | 2021 | 1736 | 0.200 |
Why?
|
| Mycoplasma | 1 | 2022 | 139 | 0.200 |
Why?
|
| Ochrobactrum anthropi | 1 | 2021 | 2 | 0.200 |
Why?
|
| Papio | 1 | 2003 | 656 | 0.200 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2016 | 157 | 0.200 |
Why?
|
| Flow Cytometry | 5 | 2015 | 5974 | 0.200 |
Why?
|
| Thermogravimetry | 1 | 2021 | 9 | 0.200 |
Why?
|
| Corynebacterium Infections | 1 | 2021 | 27 | 0.200 |
Why?
|
| Tropical Medicine | 1 | 2021 | 49 | 0.200 |
Why?
|
| Parasitic Diseases | 1 | 2021 | 75 | 0.200 |
Why?
|
| Ethanolamines | 1 | 2021 | 158 | 0.200 |
Why?
|
| Sclera | 2 | 2020 | 200 | 0.200 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2021 | 94 | 0.200 |
Why?
|
| Bioprosthesis | 2 | 2016 | 597 | 0.200 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 1540 | 0.200 |
Why?
|
| Pyrrolidinones | 1 | 2021 | 117 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2018 | 1790 | 0.190 |
Why?
|
| Epoxy Compounds | 1 | 2021 | 136 | 0.190 |
Why?
|
| Complement C5 | 1 | 2021 | 112 | 0.190 |
Why?
|
| Prednisolone | 2 | 2013 | 334 | 0.190 |
Why?
|
| Keratoconjunctivitis, Infectious | 1 | 2020 | 1 | 0.190 |
Why?
|
| Ulcer | 1 | 2002 | 209 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2021 | 1877 | 0.190 |
Why?
|
| Mucositis | 1 | 2022 | 101 | 0.190 |
Why?
|
| Meibomian Glands | 2 | 2016 | 85 | 0.190 |
Why?
|
| Graft Survival | 5 | 2016 | 3737 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 9240 | 0.190 |
Why?
|
| Fusarium | 1 | 2020 | 50 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 6 | 2023 | 6171 | 0.190 |
Why?
|
| Ciliary Body | 2 | 2021 | 173 | 0.190 |
Why?
|
| Incidence | 9 | 2022 | 20952 | 0.190 |
Why?
|
| src-Family Kinases | 3 | 2016 | 551 | 0.180 |
Why?
|
| Astigmatism | 1 | 2020 | 69 | 0.180 |
Why?
|
| Microscopy, Atomic Force | 1 | 2021 | 250 | 0.180 |
Why?
|
| Biopsy | 5 | 2017 | 6755 | 0.180 |
Why?
|
| Eye Evisceration | 1 | 2019 | 23 | 0.180 |
Why?
|
| Enzyme Activation | 5 | 2009 | 3702 | 0.180 |
Why?
|
| Onchocerciasis, Ocular | 1 | 2019 | 7 | 0.180 |
Why?
|
| Organogenesis | 1 | 2021 | 222 | 0.180 |
Why?
|
| Immunohistochemistry | 8 | 2013 | 11366 | 0.180 |
Why?
|
| Phosphorylcholine | 1 | 2020 | 162 | 0.180 |
Why?
|
| Conserved Sequence | 3 | 2019 | 1202 | 0.180 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 664 | 0.180 |
Why?
|
| Gonioscopy | 1 | 2020 | 157 | 0.180 |
Why?
|
| Trachoma | 1 | 2019 | 29 | 0.180 |
Why?
|
| Hydroxyapatites | 1 | 2020 | 75 | 0.180 |
Why?
|
| Ophthalmic Solutions | 5 | 2019 | 317 | 0.180 |
Why?
|
| Eye Enucleation | 1 | 2019 | 128 | 0.180 |
Why?
|
| Epidemics | 2 | 2019 | 523 | 0.180 |
Why?
|
| Peer Review | 1 | 2022 | 209 | 0.180 |
Why?
|
| Mice | 19 | 2021 | 81201 | 0.180 |
Why?
|
| Contact Lenses, Hydrophilic | 2 | 2020 | 64 | 0.180 |
Why?
|
| Photochemotherapy | 2 | 2017 | 807 | 0.170 |
Why?
|
| Lubricants | 1 | 2019 | 31 | 0.170 |
Why?
|
| Aspergillus fumigatus | 1 | 2020 | 150 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2019 | 357 | 0.170 |
Why?
|
| Aniridia | 1 | 2019 | 37 | 0.170 |
Why?
|
| Genomics | 6 | 2020 | 5717 | 0.170 |
Why?
|
| Leprosy | 1 | 2019 | 124 | 0.170 |
Why?
|
| Corneal Surgery, Laser | 1 | 2019 | 11 | 0.170 |
Why?
|
| Young Adult | 18 | 2020 | 56429 | 0.170 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2021 | 232 | 0.170 |
Why?
|
| Retinal Ganglion Cells | 4 | 2023 | 770 | 0.170 |
Why?
|
| Chemokines | 3 | 2012 | 970 | 0.170 |
Why?
|
| Cyanoacrylates | 1 | 2019 | 49 | 0.170 |
Why?
|
| Complement Activation | 1 | 2021 | 453 | 0.170 |
Why?
|
| Specialty Boards | 1 | 2020 | 227 | 0.170 |
Why?
|
| rho-Associated Kinases | 1 | 2020 | 279 | 0.170 |
Why?
|
| Eye, Artificial | 1 | 2018 | 18 | 0.160 |
Why?
|
| Patient Care Team | 2 | 2020 | 2531 | 0.160 |
Why?
|
| Immunity, Mucosal | 1 | 2002 | 490 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2016 | 149 | 0.160 |
Why?
|
| Human Rights | 1 | 2021 | 307 | 0.160 |
Why?
|
| Sequence Homology | 4 | 2013 | 203 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7282 | 0.160 |
Why?
|
| Blogging | 1 | 2018 | 16 | 0.160 |
Why?
|
| Child | 16 | 2020 | 77709 | 0.160 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 12961 | 0.160 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 2291 | 0.160 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 1888 | 0.160 |
Why?
|
| Cluster Analysis | 5 | 2013 | 2715 | 0.150 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2005 | 1801 | 0.150 |
Why?
|
| Evidence-Based Medicine | 3 | 2020 | 3611 | 0.150 |
Why?
|
| Substance P | 1 | 2019 | 335 | 0.150 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2017 | 27 | 0.150 |
Why?
|
| Phosphorylation | 6 | 2007 | 8436 | 0.150 |
Why?
|
| Fundus Oculi | 1 | 2019 | 473 | 0.150 |
Why?
|
| Seasons | 3 | 2018 | 1493 | 0.150 |
Why?
|
| Candida albicans | 1 | 2020 | 394 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2005 | 2453 | 0.150 |
Why?
|
| United States | 11 | 2022 | 69872 | 0.150 |
Why?
|
| Optic Nerve Injuries | 1 | 2018 | 150 | 0.150 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2020 | 712 | 0.150 |
Why?
|
| Tonometry, Ocular | 4 | 2022 | 237 | 0.150 |
Why?
|
| Disinfection | 1 | 2019 | 191 | 0.150 |
Why?
|
| Exanthema | 1 | 2022 | 501 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 253 | 0.150 |
Why?
|
| Population Surveillance | 2 | 2019 | 2616 | 0.150 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2019 | 189 | 0.140 |
Why?
|
| Base Composition | 1 | 2017 | 293 | 0.140 |
Why?
|
| Protein Transport | 3 | 2012 | 1988 | 0.140 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2018 | 130 | 0.140 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 4 | 0.140 |
Why?
|
| Chronic Disease | 5 | 2021 | 9145 | 0.140 |
Why?
|
| Cost Control | 1 | 2019 | 624 | 0.140 |
Why?
|
| Photosensitizing Agents | 3 | 2017 | 602 | 0.140 |
Why?
|
| Transcription Factor RelA | 2 | 2009 | 275 | 0.140 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 1793 | 0.140 |
Why?
|
| Aging | 1 | 2015 | 8664 | 0.140 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2018 | 323 | 0.140 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2016 | 87 | 0.140 |
Why?
|
| Hyperplasia | 2 | 2013 | 1185 | 0.140 |
Why?
|
| Metagenomics | 1 | 2019 | 428 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2021 | 1355 | 0.140 |
Why?
|
| Galectin 3 | 1 | 2018 | 227 | 0.140 |
Why?
|
| Cell Line | 6 | 2020 | 16000 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2020 | 599 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 3922 | 0.130 |
Why?
|
| Mice, Knockout | 5 | 2017 | 14561 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 2938 | 0.130 |
Why?
|
| Stress, Mechanical | 1 | 2021 | 1686 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 98 | 0.130 |
Why?
|
| Cell Survival | 2 | 2021 | 5882 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2019 | 1677 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2016 | 262 | 0.130 |
Why?
|
| Amino Acid Sequence | 5 | 2016 | 13814 | 0.130 |
Why?
|
| Dermatitis, Atopic | 1 | 2022 | 654 | 0.130 |
Why?
|
| Triamcinolone | 1 | 1995 | 68 | 0.130 |
Why?
|
| Expert Testimony | 1 | 2018 | 356 | 0.130 |
Why?
|
| Male Urogenital Diseases | 1 | 2015 | 48 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 880 | 0.130 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 6621 | 0.130 |
Why?
|
| Laser Coagulation | 1 | 2017 | 326 | 0.130 |
Why?
|
| Protein Binding | 3 | 2021 | 9384 | 0.130 |
Why?
|
| Genotype | 4 | 2018 | 12952 | 0.120 |
Why?
|
| Nanostructures | 1 | 2020 | 551 | 0.120 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2015 | 55 | 0.120 |
Why?
|
| Granuloma | 1 | 2017 | 319 | 0.120 |
Why?
|
| Necrosis | 2 | 2016 | 1643 | 0.120 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 1400 | 0.120 |
Why?
|
| Lasers, Excimer | 1 | 2015 | 72 | 0.120 |
Why?
|
| Swine | 6 | 2021 | 5918 | 0.120 |
Why?
|
| Water | 1 | 2021 | 1395 | 0.120 |
Why?
|
| Retinal Degeneration | 1 | 2018 | 415 | 0.120 |
Why?
|
| Transplantation, Heterologous | 2 | 2021 | 2383 | 0.120 |
Why?
|
| Exudates and Transudates | 2 | 2014 | 172 | 0.120 |
Why?
|
| Basement Membrane | 1 | 2015 | 357 | 0.120 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 354 | 0.120 |
Why?
|
| Hematopoiesis | 2 | 2021 | 2073 | 0.120 |
Why?
|
| Protein Isoforms | 1 | 2019 | 1730 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2004 | 5023 | 0.120 |
Why?
|
| Acanthamoeba castellanii | 1 | 2013 | 10 | 0.120 |
Why?
|
| Adolescent | 15 | 2020 | 85779 | 0.120 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2015 | 88 | 0.120 |
Why?
|
| Trigeminal Nerve | 1 | 2015 | 249 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2023 | 3424 | 0.120 |
Why?
|
| Apoptosis | 5 | 2023 | 9724 | 0.120 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2014 | 65 | 0.120 |
Why?
|
| Genital Diseases, Female | 1 | 2015 | 197 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2017 | 811 | 0.120 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2013 | 56 | 0.110 |
Why?
|
| Prosthesis Coloring | 1 | 2013 | 31 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2020 | 687 | 0.110 |
Why?
|
| Nucleic Acid Conformation | 1 | 2017 | 913 | 0.110 |
Why?
|
| Inflammation | 3 | 2021 | 10637 | 0.110 |
Why?
|
| Interferon Type I | 1 | 2017 | 542 | 0.110 |
Why?
|
| Gene Expression | 4 | 2021 | 7798 | 0.110 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 3154 | 0.110 |
Why?
|
| Physician Executives | 1 | 2014 | 128 | 0.110 |
Why?
|
| Histiocytes | 1 | 2013 | 103 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 13693 | 0.110 |
Why?
|
| Regeneration | 1 | 2022 | 1485 | 0.110 |
Why?
|
| Developing Countries | 2 | 2019 | 2815 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 480 | 0.110 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 422 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 4554 | 0.110 |
Why?
|
| Vision Disorders | 1 | 2020 | 1058 | 0.110 |
Why?
|
| Ocular Hypertension | 1 | 2014 | 198 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 720 | 0.110 |
Why?
|
| Goblet Cells | 1 | 2016 | 287 | 0.110 |
Why?
|
| Epidermis | 1 | 2016 | 528 | 0.110 |
Why?
|
| Monkeypox virus | 2 | 2023 | 48 | 0.110 |
Why?
|
| Corneal Opacity | 1 | 2013 | 60 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 489 | 0.110 |
Why?
|
| Zoonoses | 3 | 2020 | 185 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 465 | 0.110 |
Why?
|
| Models, Immunological | 1 | 2015 | 527 | 0.110 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2013 | 145 | 0.110 |
Why?
|
| Blotting, Western | 4 | 2016 | 5181 | 0.110 |
Why?
|
| Cysts | 2 | 2017 | 678 | 0.110 |
Why?
|
| Actins | 1 | 2020 | 2121 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 1783 | 0.110 |
Why?
|
| Descemet Membrane | 1 | 2013 | 73 | 0.110 |
Why?
|
| AIDS Vaccines | 1 | 2019 | 938 | 0.110 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2018 | 429 | 0.110 |
Why?
|
| Myopia | 1 | 2015 | 254 | 0.110 |
Why?
|
| Wet Macular Degeneration | 1 | 2014 | 145 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2012 | 107 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3135 | 0.100 |
Why?
|
| User-Computer Interface | 1 | 2019 | 1431 | 0.100 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 5321 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3242 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2013 | 263 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2016 | 541 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1410 | 0.100 |
Why?
|
| Myofibroblasts | 1 | 2013 | 222 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2016 | 3144 | 0.100 |
Why?
|
| Medical Informatics | 1 | 2019 | 745 | 0.100 |
Why?
|
| DNA Replication | 1 | 2018 | 1399 | 0.100 |
Why?
|
| Retinal Detachment | 1 | 2015 | 411 | 0.100 |
Why?
|
| Neuroprotective Agents | 3 | 2018 | 941 | 0.100 |
Why?
|
| Endothelium, Corneal | 3 | 2022 | 199 | 0.100 |
Why?
|
| Polychondritis, Relapsing | 1 | 2011 | 28 | 0.100 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2013 | 215 | 0.100 |
Why?
|
| Uvea | 2 | 2017 | 31 | 0.100 |
Why?
|
| Ophthalmic Nerve | 1 | 2011 | 43 | 0.100 |
Why?
|
| Electromagnetic Fields | 1 | 2013 | 298 | 0.100 |
Why?
|
| Magnetite Nanoparticles | 1 | 2013 | 321 | 0.100 |
Why?
|
| Tissue Adhesives | 1 | 2013 | 179 | 0.100 |
Why?
|
| Trimethoprim | 2 | 2021 | 91 | 0.100 |
Why?
|
| Antibodies, Antinuclear | 1 | 2012 | 326 | 0.100 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2013 | 115 | 0.100 |
Why?
|
| Communicable Diseases | 1 | 2019 | 880 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1856 | 0.100 |
Why?
|
| Cytokines | 3 | 2021 | 7323 | 0.100 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2013 | 192 | 0.100 |
Why?
|
| Leukocytes | 2 | 2010 | 2045 | 0.090 |
Why?
|
| Nerve Degeneration | 1 | 2015 | 748 | 0.090 |
Why?
|
| Dimethylallyltranstransferase | 1 | 2010 | 8 | 0.090 |
Why?
|
| Risk Factors | 6 | 2022 | 72296 | 0.090 |
Why?
|
| Alginates | 1 | 2012 | 252 | 0.090 |
Why?
|
| Immunoblotting | 2 | 2005 | 1683 | 0.090 |
Why?
|
| Molecular Chaperones | 2 | 2022 | 743 | 0.090 |
Why?
|
| Hypertrophy | 1 | 2012 | 569 | 0.090 |
Why?
|
| Eye Abnormalities | 1 | 2013 | 246 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2017 | 6542 | 0.090 |
Why?
|
| Choroid | 1 | 2012 | 322 | 0.090 |
Why?
|
| Durapatite | 1 | 2011 | 161 | 0.090 |
Why?
|
| Ecosystem | 1 | 2014 | 474 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 2232 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2012 | 23404 | 0.090 |
Why?
|
| Infant, Newborn | 5 | 2019 | 25628 | 0.090 |
Why?
|
| Ribonucleoproteins | 1 | 2012 | 381 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 1061 | 0.090 |
Why?
|
| Nerve Regeneration | 1 | 2015 | 788 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 6489 | 0.090 |
Why?
|
| DNA, Fungal | 1 | 2011 | 280 | 0.090 |
Why?
|
| Comorbidity | 2 | 2021 | 10388 | 0.090 |
Why?
|
| Tyrosine | 2 | 2005 | 1462 | 0.090 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2011 | 319 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1796 | 0.090 |
Why?
|
| Virus Activation | 1 | 2011 | 319 | 0.090 |
Why?
|
| France | 1 | 2010 | 517 | 0.090 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 2019 | 0.080 |
Why?
|
| Massachusetts | 3 | 2020 | 8662 | 0.080 |
Why?
|
| Antigens, Viral | 2 | 2011 | 1035 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2017 | 1248 | 0.080 |
Why?
|
| Species Specificity | 3 | 2020 | 2478 | 0.080 |
Why?
|
| Morbidity | 3 | 2020 | 1768 | 0.080 |
Why?
|
| Epithelium | 2 | 2005 | 1679 | 0.080 |
Why?
|
| Genes, Viral | 1 | 2010 | 718 | 0.080 |
Why?
|
| Physician's Role | 1 | 2016 | 943 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 3505 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 8642 | 0.080 |
Why?
|
| I-kappa B Kinase | 1 | 2009 | 252 | 0.080 |
Why?
|
| Age of Onset | 1 | 2015 | 3270 | 0.080 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 714 | 0.080 |
Why?
|
| Prednisone | 1 | 2013 | 1574 | 0.080 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2008 | 45 | 0.080 |
Why?
|
| Recurrence | 3 | 2011 | 8340 | 0.080 |
Why?
|
| Public Health Practice | 1 | 2010 | 218 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 657 | 0.080 |
Why?
|
| Mycophenolic Acid | 1 | 2010 | 343 | 0.080 |
Why?
|
| Mice, Inbred C3H | 1 | 2009 | 964 | 0.080 |
Why?
|
| Kinetics | 2 | 2021 | 6476 | 0.080 |
Why?
|
| Vascular Malformations | 1 | 2013 | 454 | 0.080 |
Why?
|
| Keratinocytes | 1 | 2012 | 799 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 644 | 0.080 |
Why?
|
| Autoantigens | 1 | 2012 | 892 | 0.080 |
Why?
|
| Synaptotagmin I | 1 | 2008 | 36 | 0.080 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 9735 | 0.080 |
Why?
|
| Herpesvirus 1, Human | 2 | 2011 | 743 | 0.080 |
Why?
|
| Chemokine CXCL10 | 2 | 2006 | 305 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 7721 | 0.080 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2007 | 15 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 12073 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3486 | 0.070 |
Why?
|
| Nerve Fibers | 3 | 2023 | 687 | 0.070 |
Why?
|
| Health Promotion | 1 | 2019 | 2205 | 0.070 |
Why?
|
| Serpins | 1 | 2009 | 247 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 225 | 0.070 |
Why?
|
| Mycoses | 1 | 2010 | 376 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3595 | 0.070 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 25039 | 0.070 |
Why?
|
| Neutrophil Infiltration | 1 | 2009 | 391 | 0.070 |
Why?
|
| Inpatients | 1 | 2019 | 2518 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2019 | 264 | 0.070 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 894 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2012 | 685 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1461 | 0.070 |
Why?
|
| Publishing | 1 | 2014 | 833 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 2839 | 0.070 |
Why?
|
| Phenotype | 3 | 2010 | 16367 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2013 | 2943 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2010 | 9955 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2009 | 675 | 0.070 |
Why?
|
| Wound Healing | 2 | 2020 | 2785 | 0.070 |
Why?
|
| RNA Splicing | 1 | 2011 | 908 | 0.070 |
Why?
|
| BALB 3T3 Cells | 1 | 2006 | 9 | 0.070 |
Why?
|
| Child, Preschool | 7 | 2019 | 41005 | 0.070 |
Why?
|
| Pan troglodytes | 2 | 2019 | 229 | 0.070 |
Why?
|
| Mutation | 4 | 2022 | 29786 | 0.070 |
Why?
|
| Surgical Flaps | 1 | 2015 | 1640 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 1338 | 0.070 |
Why?
|
| Bacillus | 1 | 2006 | 77 | 0.070 |
Why?
|
| Time Factors | 4 | 2016 | 40075 | 0.070 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2006 | 156 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2011 | 1057 | 0.070 |
Why?
|
| Telemedicine | 2 | 2020 | 2872 | 0.070 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2005 | 14 | 0.070 |
Why?
|
| Rodentia | 1 | 2007 | 261 | 0.070 |
Why?
|
| Anesthesia, General | 1 | 2013 | 1171 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2009 | 574 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2010 | 1851 | 0.070 |
Why?
|
| Integrin alphaV | 1 | 2005 | 55 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 472 | 0.070 |
Why?
|
| Chromones | 1 | 2005 | 154 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2021 | 1958 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 2278 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4479 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3773 | 0.070 |
Why?
|
| China | 3 | 2018 | 2245 | 0.060 |
Why?
|
| Absorption | 1 | 2005 | 248 | 0.060 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2004 | 362 | 0.060 |
Why?
|
| Fluorometry | 2 | 2016 | 106 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10483 | 0.060 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2004 | 27 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2005 | 286 | 0.060 |
Why?
|
| Pneumonia | 1 | 2016 | 2133 | 0.060 |
Why?
|
| Corneal Topography | 2 | 2016 | 69 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 638 | 0.060 |
Why?
|
| Optic Nerve | 2 | 2023 | 554 | 0.060 |
Why?
|
| Mitomycin | 1 | 2005 | 259 | 0.060 |
Why?
|
| Cell Separation | 1 | 2010 | 1751 | 0.060 |
Why?
|
| Congresses as Topic | 2 | 2020 | 764 | 0.060 |
Why?
|
| Quality of Life | 2 | 2016 | 12802 | 0.060 |
Why?
|
| Genetic Loci | 1 | 2013 | 2575 | 0.060 |
Why?
|
| Interleukin-1beta | 2 | 2020 | 972 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2020 | 2556 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2008 | 822 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2011 | 1547 | 0.060 |
Why?
|
| Telangiectasis | 1 | 2004 | 76 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 2104 | 0.060 |
Why?
|
| Quinones | 1 | 2003 | 76 | 0.060 |
Why?
|
| Rifabutin | 1 | 2003 | 52 | 0.060 |
Why?
|
| Virus Diseases | 2 | 2017 | 711 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 430 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2004 | 1159 | 0.060 |
Why?
|
| Ophthalmoscopy | 1 | 2004 | 176 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 898 | 0.060 |
Why?
|
| Anti-Allergic Agents | 1 | 2004 | 141 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2013 | 1940 | 0.060 |
Why?
|
| Ear Cartilage | 1 | 2023 | 62 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 1988 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 1431 | 0.060 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2003 | 158 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2023 | 137 | 0.050 |
Why?
|
| Isoindoles | 1 | 2022 | 41 | 0.050 |
Why?
|
| Itraconazole | 1 | 2002 | 43 | 0.050 |
Why?
|
| Trifluridine | 1 | 2022 | 29 | 0.050 |
Why?
|
| Cohort Studies | 8 | 2020 | 40559 | 0.050 |
Why?
|
| Benzoquinones | 1 | 2003 | 201 | 0.050 |
Why?
|
| Virulence Factors | 1 | 2006 | 509 | 0.050 |
Why?
|
| Androstadienes | 1 | 2004 | 345 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2038 | 0.050 |
Why?
|
| Cell Count | 3 | 2012 | 1856 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 16690 | 0.050 |
Why?
|
| Interleukin-1 | 2 | 2003 | 1263 | 0.050 |
Why?
|
| Fluconazole | 1 | 2002 | 146 | 0.050 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2002 | 120 | 0.050 |
Why?
|
| Morpholines | 1 | 2005 | 571 | 0.050 |
Why?
|
| Materials Testing | 2 | 2018 | 867 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2007 | 1284 | 0.050 |
Why?
|
| Histocytochemistry | 1 | 2003 | 719 | 0.050 |
Why?
|
| Tissue Donors | 3 | 2018 | 2241 | 0.050 |
Why?
|
| Macaca | 1 | 2023 | 440 | 0.050 |
Why?
|
| Focal Adhesions | 1 | 2002 | 121 | 0.050 |
Why?
|
| Peyer's Patches | 1 | 2002 | 121 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2002 | 182 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 3799 | 0.050 |
Why?
|
| Polymyxins | 1 | 2021 | 22 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2018 | 2297 | 0.050 |
Why?
|
| Corynebacterium | 1 | 2021 | 47 | 0.050 |
Why?
|
| Virus Attachment | 1 | 2021 | 55 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 4777 | 0.050 |
Why?
|
| Lactams, Macrocyclic | 1 | 2003 | 320 | 0.050 |
Why?
|
| HIV-1 | 1 | 2019 | 6939 | 0.050 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2022 | 165 | 0.050 |
Why?
|
| Ceftazidime | 1 | 2021 | 69 | 0.050 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2020 | 16 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2007 | 4222 | 0.050 |
Why?
|
| Polymyxin B | 1 | 2020 | 46 | 0.050 |
Why?
|
| Amino Acids | 2 | 2022 | 1737 | 0.050 |
Why?
|
| Benzalkonium Compounds | 1 | 2020 | 24 | 0.050 |
Why?
|
| Biguanides | 1 | 2020 | 23 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 315 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2022 | 443 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2009 | 2969 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 19905 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2016 | 3712 | 0.050 |
Why?
|
| Pinocytosis | 1 | 2020 | 65 | 0.050 |
Why?
|
| Ectropion | 1 | 2020 | 26 | 0.050 |
Why?
|
| Health Surveys | 1 | 2010 | 4036 | 0.050 |
Why?
|
| Multilocus Sequence Typing | 1 | 2020 | 100 | 0.050 |
Why?
|
| Clathrin-Coated Vesicles | 1 | 2020 | 74 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2005 | 1619 | 0.050 |
Why?
|
| Integrins | 1 | 2004 | 846 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 9274 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2023 | 670 | 0.050 |
Why?
|
| Pan paniscus | 1 | 2019 | 5 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2015 | 7730 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 2638 | 0.040 |
Why?
|
| Prevalence | 3 | 2021 | 15221 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2021 | 594 | 0.040 |
Why?
|
| p21-Activated Kinases | 1 | 2020 | 128 | 0.040 |
Why?
|
| Phenylalanine | 1 | 2021 | 365 | 0.040 |
Why?
|
| Cell Movement | 2 | 2018 | 5218 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2019 | 1741 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2015 | 1590 | 0.040 |
Why?
|
| Valine | 1 | 2021 | 413 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2003 | 973 | 0.040 |
Why?
|
| Isoelectric Point | 1 | 2019 | 80 | 0.040 |
Why?
|
| Estradiol | 1 | 2007 | 2020 | 0.040 |
Why?
|
| Steroids | 1 | 2004 | 930 | 0.040 |
Why?
|
| Decorin | 1 | 2019 | 40 | 0.040 |
Why?
|
| Infant | 5 | 2019 | 35134 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 449 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2012 | 5984 | 0.040 |
Why?
|
| Boston | 1 | 2012 | 9312 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2020 | 294 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 475 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 1607 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 409 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2020 | 772 | 0.040 |
Why?
|
| Conjunctivitis, Viral | 1 | 2018 | 6 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2019 | 231 | 0.040 |
Why?
|
| Burkina Faso | 1 | 2018 | 88 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 5867 | 0.040 |
Why?
|
| Sri Lanka | 1 | 2018 | 90 | 0.040 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 222 | 0.040 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2018 | 24 | 0.040 |
Why?
|
| Horses | 1 | 2019 | 304 | 0.040 |
Why?
|
| Vancomycin | 1 | 2021 | 501 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 1678 | 0.040 |
Why?
|
| HLA-B Antigens | 1 | 2019 | 354 | 0.040 |
Why?
|
| Sodium Hydroxide | 1 | 2017 | 44 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 788 | 0.040 |
Why?
|
| Visual Field Tests | 1 | 2019 | 383 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2010 | 3208 | 0.040 |
Why?
|
| Proline | 1 | 2019 | 458 | 0.040 |
Why?
|
| Mice, Inbred DBA | 2 | 2009 | 642 | 0.040 |
Why?
|
| Mitochondria | 1 | 2010 | 3514 | 0.040 |
Why?
|
| Cell Division | 1 | 2004 | 4569 | 0.040 |
Why?
|
| Alleles | 2 | 2019 | 6933 | 0.040 |
Why?
|
| Submandibular Gland | 1 | 2017 | 86 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2023 | 21748 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 2504 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2021 | 2327 | 0.040 |
Why?
|
| Uveitis, Anterior | 1 | 2017 | 101 | 0.040 |
Why?
|
| Cautery | 1 | 2017 | 72 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6386 | 0.040 |
Why?
|
| Interleukin-18 | 2 | 2009 | 249 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2019 | 980 | 0.040 |
Why?
|
| Blinking | 1 | 2017 | 138 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 114 | 0.030 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 2703 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 1525 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2006 | 3203 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 14723 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 674 | 0.030 |
Why?
|
| Gels | 1 | 2017 | 427 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2019 | 837 | 0.030 |
Why?
|
| Cytosol | 1 | 2019 | 901 | 0.030 |
Why?
|
| Organ Preservation | 1 | 2018 | 331 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2015 | 74 | 0.030 |
Why?
|
| Axons | 1 | 2023 | 1685 | 0.030 |
Why?
|
| Proteome | 2 | 2019 | 1798 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 1865 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 3707 | 0.030 |
Why?
|
| Galectins | 1 | 2018 | 268 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 1240 | 0.030 |
Why?
|
| Proteins | 1 | 2010 | 6100 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2020 | 1074 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 2086 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 266 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2016 | 520 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2020 | 1539 | 0.030 |
Why?
|
| Lacrimal Apparatus | 1 | 2017 | 225 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 1206 | 0.030 |
Why?
|
| Artifacts | 1 | 2023 | 1904 | 0.030 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 296 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2023 | 4208 | 0.030 |
Why?
|
| Collagenases | 1 | 2014 | 228 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 1656 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2021 | 53290 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2020 | 1275 | 0.030 |
Why?
|
| Trophozoites | 1 | 2013 | 12 | 0.030 |
Why?
|
| Brazil | 1 | 2018 | 1270 | 0.030 |
Why?
|
| International Cooperation | 1 | 2020 | 1420 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2014 | 302 | 0.030 |
Why?
|
| Endotamponade | 1 | 2013 | 35 | 0.030 |
Why?
|
| Immunodiffusion | 1 | 2012 | 163 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 657 | 0.030 |
Why?
|
| Aqueous Humor | 1 | 2013 | 161 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2014 | 344 | 0.030 |
Why?
|
| Haplorhini | 1 | 2013 | 552 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3854 | 0.030 |
Why?
|
| Cholesterol | 2 | 2013 | 2919 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2013 | 98 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 1366 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2018 | 1184 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2013 | 420 | 0.030 |
Why?
|
| Air | 1 | 2013 | 182 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 965 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 6111 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2012 | 144 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2012 | 148 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 354 | 0.030 |
Why?
|
| Eye Foreign Bodies | 1 | 2013 | 55 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 21696 | 0.030 |
Why?
|
| Injections | 1 | 1995 | 840 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 2173 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 1117 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 2902 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 950 | 0.030 |
Why?
|
| India | 1 | 2018 | 2197 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 1375 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 2184 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2016 | 1252 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2012 | 214 | 0.020 |
Why?
|
| Models, Molecular | 2 | 2013 | 5451 | 0.020 |
Why?
|
| Electrophysiological Phenomena | 1 | 2013 | 315 | 0.020 |
Why?
|
| Indazoles | 1 | 2013 | 290 | 0.020 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2011 | 144 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 2274 | 0.020 |
Why?
|
| Shear Strength | 1 | 2011 | 165 | 0.020 |
Why?
|
| Cell Shape | 1 | 2012 | 375 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 1 | 2012 | 184 | 0.020 |
Why?
|
| Leptin | 1 | 2019 | 1600 | 0.020 |
Why?
|
| Calibration | 1 | 2013 | 816 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 2016 | 506 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 1423 | 0.020 |
Why?
|
| Peptides | 1 | 2002 | 4410 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2012 | 758 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 4328 | 0.020 |
Why?
|
| Serotyping | 1 | 2010 | 338 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 4666 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2020 | 4026 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2649 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 768 | 0.020 |
Why?
|
| Disease Progression | 2 | 2019 | 13286 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2011 | 963 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2012 | 527 | 0.020 |
Why?
|
| Systems Biology | 1 | 2013 | 469 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2016 | 1487 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 3511 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 1475 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 2219 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2010 | 1375 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2013 | 1525 | 0.020 |
Why?
|
| Drainage | 1 | 2014 | 1142 | 0.020 |
Why?
|
| Prognosis | 3 | 2013 | 29060 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 500 | 0.020 |
Why?
|
| Video Recording | 1 | 2013 | 949 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2013 | 1767 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2009 | 1085 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2013 | 798 | 0.020 |
Why?
|
| Nervous System | 1 | 2011 | 554 | 0.020 |
Why?
|
| Peromyscus | 1 | 2007 | 18 | 0.020 |
Why?
|
| Digoxigenin | 1 | 2007 | 26 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2009 | 529 | 0.020 |
Why?
|
| Sciuridae | 1 | 2007 | 78 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2010 | 5388 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2007 | 135 | 0.020 |
Why?
|
| Endoscopy | 1 | 2017 | 1787 | 0.020 |
Why?
|
| Connective Tissue Cells | 1 | 2006 | 55 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2007 | 152 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3338 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 300 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2088 | 0.020 |
Why?
|
| Drug Implants | 1 | 2007 | 244 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3954 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2006 | 256 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 4042 | 0.020 |
Why?
|
| Immune System | 1 | 2011 | 806 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2007 | 213 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 1539 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 10183 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 1655 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 4010 | 0.020 |
Why?
|
| Suspensions | 1 | 2004 | 65 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 758 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2007 | 661 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2007 | 514 | 0.020 |
Why?
|
| Fluorometholone | 1 | 2004 | 5 | 0.020 |
Why?
|
| Registries | 1 | 2020 | 8091 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 2960 | 0.010 |
Why?
|
| Fluorescein | 1 | 2004 | 171 | 0.010 |
Why?
|
| Cell Death | 1 | 2009 | 1707 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1683 | 0.010 |
Why?
|
| Reoperation | 1 | 2013 | 4201 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15078 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2003 | 352 | 0.010 |
Why?
|
| Trigeminal Ganglion | 1 | 2003 | 186 | 0.010 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2002 | 48 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2007 | 981 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12788 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2006 | 1465 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2009 | 3001 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 4185 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11486 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.010 |
Why?
|
| Transfection | 1 | 2009 | 5895 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2004 | 1101 | 0.010 |
Why?
|
| Linear Models | 1 | 2010 | 5953 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 1186 | 0.010 |
Why?
|
| Family | 1 | 2010 | 3147 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1799 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2009 | 3493 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 4320 | 0.010 |
Why?
|
| Pregnancy | 1 | 2018 | 29144 | 0.010 |
Why?
|
| Immunity | 1 | 2002 | 1014 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 17446 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 8319 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20130 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 12025 | 0.010 |
Why?
|
| Obesity | 1 | 2010 | 12746 | 0.000 |
Why?
|